The Biomedical Advanced Research and Development Authority (BARDA), a unique part of the U.S. Department of Health and Human Services, partners with biotechnology firms large and small to develop and make available medical countermeasures such as vaccines, therapeutics, and diagnostics to meet the threat of chemical, biological, radiological agents, emerging infectious diseases, and pandemic influenza. In fiscal year 2018, BARDA invested $1.4B in the advanced development and acquisition of products to address an array of threats, from Zika to Ebola. Last year, BARDA launched the Division of Research, Innovation, and Ventures (DRIVe) to accelerate the development and availability of transformative technologies and approaches to health security “threats”.
Rick Bright, PhD, Director of BARDA, will be in attendance to provide an overview of BARDA’s unique approach to public-private partnerships.
BARDA is seeking new partners in the following areas:
Early and/or pre-symptomatic disease detection
Transformative production technologies
Diagnostics for use outside of medical settings
New approaches respiratory protection
Novel vaccine and drug administration
New approaches to diagnose, treat and prevent influenza infection
Approaches to address the threat of antimicrobial resistant
Approaches to address sepsis